Safety and tolerability profile of JEMPERLI1

Laboratory abnormalities

Chart displaying laboratory abnormalities that worsened from baseline to Grade 3 or 4 Occurring in less than 1% of patients with dMMR Endometrial Cancer Receiving JEMPERLI (dostarlimab-gxly) in GARNET

Early identification and management of immune-mediated adverse reactions are essential to ensure safe use of PD-1/PD-L1–blocking antibodies.1

*Intention-to-treat population (N=104).

Consists of new onset of laboratory abnormality or worsening of baseline laboratory abnormality.

Icon: JEMPERLI (dostarlimab-gxly) Dosing and Administration

Find out how to dose and
administer JEMPERLI.

Icon: JEMPERLI (dostarlimab-gxly) Support

Get support for
JEMPERLI at every step.

Icon: JEMPERLI (dostarlimab-gxly) Trial

Explore the pivotal trial